Silence Therapeutics (SLN) Gains from Investment Securities (2021 - 2025)
Historic Gains from Investment Securities for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to -$2.9 million.
- Silence Therapeutics' Gains from Investment Securities fell 254977.8% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 64049.1%. This contributed to the annual value of $17.5 million for FY2024, which is 44259.84% up from last year.
- Per Silence Therapeutics' latest filing, its Gains from Investment Securities stood at -$2.9 million for Q3 2025, which was down 254977.8% from -$420000.0 recorded in Q2 2025.
- Silence Therapeutics' Gains from Investment Securities' 5-year high stood at $19.7 million during Q4 2023, with a 5-year trough of -$2.9 million in Q3 2025.
- Its 5-year average for Gains from Investment Securities is $3.6 million, with a median of -$108144.4 in 2024.
- As far as peak fluctuations go, Silence Therapeutics' Gains from Investment Securities surged by 4497.34% in 2023, and later plummeted by 254977.8% in 2025.
- Silence Therapeutics' Gains from Investment Securities (Quarter) stood at -$406682.1 in 2021, then skyrocketed by 3437.38% to $13.6 million in 2022, then soared by 44.97% to $19.7 million in 2023, then crashed by 62.61% to $7.4 million in 2024, then plummeted by 139.3% to -$2.9 million in 2025.
- Its Gains from Investment Securities stands at -$2.9 million for Q3 2025, versus -$420000.0 for Q2 2025 and -$89000.0 for Q1 2025.